Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 24 , ISSUE S3 ( April, 2020 ) > List of Articles

INVITED ARTICLE

Extracorporeal Therapy in Sepsis

Praveen Kumar G

Keywords : Cytokines, Endotoxin, Extracorporeal therapy, Sepsis

Citation Information : G P K. Extracorporeal Therapy in Sepsis. Indian J Crit Care Med 2020; 24 (S3):117-121.

DOI: 10.5005/jp-journals-10071-23382

License: CC BY-NC 4.0

Published Online: 01-04-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Manuscript A, Trials R. NIH public access. 2014;41(9):2209–2220.
  2. Angus DC, Van Der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369(9):840–851. DOI: 10.1056/NEJMra1208623.
  3. Prince LR, Whyte MK, Sabroe I, Parker LC. The role of TLRs in neutrophil activation. Curr Opin Pharmacol 2011;11(4):397–403. DOI: 10.1016/j.coph.2011.06.007.
  4. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, et al. Science in medicine alarmins: awaiting a clinical response. J Clin Invest 2012;122(8):2711–2719. DOI: 10.1172/JCI62423.
  5. Monard C, Rimmelé T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif 2019;47(Suppl 3):2–15. DOI: 10.1159/000499520.
  6. Cavaillon JM, Munoz C, Fitting C, Misset B, Carlet J. Circulating cytokines: the tip of the iceberg? Circ Shock 1992;38(2):145–152.
  7. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27(9):792–801. DOI: 10.1046/j.1525-1594.2003.07289.x.
  8. Honore PM, Hoste E, Molnár Z, Jacobs R, Joannes-Boyau O, Malbrain MLNG, et al. Cytokine removal in human septic shock: where are we and where are we going? Ann Intensive Care 2019;9(1):56. DOI: 10.1186/s13613-019-0530-y.
  9. Honoré PM, Jacobs R, Boer W, Joannes-Boyau O, De Regt J, De Waele E, et al. New insights regarding rationale, therapeutic target and dose of hemofiltration and hybrid therapies in septic acute kidney injury. Blood Purif 2012;33:(1-3):44–51. DOI: 10.1159/000333837.
  10. De Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA. Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med 1999;25:(9):903–910. DOI: 10.1007/s001340050981.
  11. Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013;39(9):1535–1546. DOI: 10.1007/s00134-013-2967-z.
  12. Borthwick EMJ, Hill CJ, Rabindranath KS, Maxwell AP, McAuley DF, Blackwood B. High-volume haemofiltration for sepsis in adults (review) summary of findings for the main comparison. Cochrane Database Syst Rev 2017; 2017(1):CD008075.
  13. Friesecke S, Stecher SS, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs 2017;20(3):252–259. DOI: 10.1007/s10047-017-0967-4.
  14. Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017;21(1):1–10. DOI: 10.1186/s13054-017-1662-9.
  15. Schädler D, Porzelius C, Jörres A, Marx G, Meier-Hellmann A, Putensen C, et al. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. Crit Care 2013;17(S2):P62. DOI: 10.1186/cc12000.
  16. Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE 2017;12(10):1–19. DOI: 10.1371/journal.pone.0187015.
  17. Hawchar F, László I, Öveges N, Trásy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care 2019;49:172–178. DOI: 10.1016/j.jcrc.2018.11.003.
  18. Formica M, Inguaggiato P, Bainotti S, Lou. WM. Coupled plasma filtration adsorption. Contrib Nephrol 2007;156:405–410. DOI: 10.1159/000102131.
  19. Ronco C, Brendolan A, D’Intini V, Ricci Z, Lou WM, Bellomo R. Coupled plasma filtration adsorption: rationale, technical development and early clinical experience. Blood Purif 2003;21(6):409–416. DOI: 10.1159/000073444.
  20. Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 2014;4(1):1–10. DOI: 10.1136/bmjopen-2013-003536.
  21. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of Polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. J Am Med Assoc 2009;301(23):2445–2452. DOI: 10.1001/jama.2009.856.
  22. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015;41(6):975–984. DOI: 10.1007/s00134-015-3751-z.
  23. Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. J Am Med Assoc 2018;320(14):1455–1463. DOI: 10.1001/jama.2018.14618.
  24. Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018;44(2):167–178. DOI: 10.1007/s00134-017-5004-9.
  25. Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp 2018;6(1). DOI: 10.1186/s40635-018-0177-2.
  26. Knaup H, Stahl K, Schmidt BMW, Idowu TO, Busch M, Wiesner O, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care 2018;22(1):1–11. DOI: 10.1186/s13054-018-2220-9.
  27. Sanford K. Extracorporeal photopheresis: clinical use so far. J Clin Apher 2013;28:349–355.
  28. Long EJ, Taylor A, Delzoppo C, Shann F, Pearson G, Buckley D, et al. A randomised controlled trial of plasma filtration in severe paediatric sepsis. Crit Care Resusc 2013;15(3):198–204.
  29. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, et al. Continuous plasmafiltration in sepsis syndrome. Crit Care Med 1999;27(10):2096–2104. DOI: 10.1097/00003246-199910000-00003.
  30. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002;28(10):1434–1439. DOI: 10.1007/s00134-002-1410-7.
  31. Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, Marshall JC, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care 2014;18(1):1–8. DOI: 10.1186/s13054-014-0699-2.
  32. Tumlin JA, Galphin CM, Tolwani AJ, Chan MR, Vijayan A, Finkel K, et al. A multi-center, randomized, controlled, pivotal study to assess the safety and efficacy of a selective cytopheretic device in patients with acute kidney injury. PLoS ONE 2015;10(8):e0132482. DOI: 10.1371/journal.pone.0132482.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.